Somewhere in your inbox is a vendor email that says peptides are back.
Six of them did clear an FDA advisory committee in July. That is real. What it is not is permission. The gap between those two things is where clinics lose money this year — and in at least one case, their freedom to practice.
Here is how to read the difference.
📡 The Radar
1. The PCAC six: an advisory vote authorizes nothing. At its July 23–24 meeting, FDA’s Pharmacy Compounding Advisory Committee recommended adding six bulk peptide substances to the 503A list — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — and declined to recommend a seventh, emideltide (DSIP) (FDA PCAC page). The recommendations are nonbinding. Counsel analyzing the meeting note only two mechanisms can actually change the rule: formal notice-and-comment rulemaking, or Congress amending the FDCA (Holland & Knight analysis). Neither has happened. There is no Federal Register rule adding these six to the list today. What it means for your clinic: if a supplier tells you a peptide is “approved for compounding now,” ask for the Federal Register citation. Not the vote, not the press release, not the webinar slide — the citation. There isn’t one yet. A catalog you expand on an advisory vote is a catalog you may be unwinding at your own cost.
2. Enforcement moved from the sellers to a prescriber. On April 1, a federal grand jury in Utah indicted a licensed osteopathic physician, alleging he received peptides imported from China through a middleman, affixed his own labels to the vials, and dispensed them to more than two hundred patients between February 2024 and April 2025. The charges are receipt in interstate commerce of misbranded drugs and delivery for pay of misbranded drugs with intent to defraud (DOJ, District of Utah). An indictment is an allegation. The defendant is presumed innocent unless and until proven guilty.
Read the mechanism, not the verdict. The alleged offense is not “prescribed a peptide.” It is misbranding — labels that did not disclose the manufacturer, packer, or distributor. That is a paperwork failure with a criminal statute attached to it.
Meanwhile the seller-side sweep continued: FDA posted warning letters dated August 24 to a group of online peptide sellers — Royal Peptides, Peptide Partners, Peak Performance Peptides, NuScience Peptides, and TXP Innovations d/b/a Tex Peptides — for marketing unapproved injectables behind “research use only” labels (Peptide Partners letter). What it means: the question “where did this vial come from” now has a criminal-exposure answer attached to it, and the answer runs through the prescriber, not just the supplier. If you cannot produce, today, a documented chain from a licensed source for every vial in your fridge, that is the highest-value hour of work available to you this week.
3. The adverse-event file on compounded GLP-1s is now a public number. As of May 31, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency’s own caveat matters as much as the count: “federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported” (FDA, updated 09/01/2026). What it means: adverse-event clusters precede enforcement. They are the leading indicator, and this one is published, rising, and explicitly described by the agency as an undercount. A meaningful share of the reports FDA has flagged involve dosing errors — patients confused by syringe unit markings. That is a patient-education problem you can fix in your own clinic this month, independent of any rulemaking.
🔭 The Watchlist
The PCAC has already announced a second round: the committee will meet before the end of February 2027 to consider five more peptides — cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF (FDA meeting page). Expect a fresh round of “it’s coming” vendor emails in Q1. Same test applies: citation or it isn’t real.
On the state side, Florida’s Medical Spa Prescription Drug Oversight Act (SB 1728 / HB 1429) was introduced in January and died in committee in March, so nothing has changed there yet — but the fact that it was written at all tells you where state legislatures are pointed. We’re tracking AZ, TX and FL board activity for a future issue.
🔧 The Operator Lesson: the weekly regulatory half-hour
Most clinics learn about regulatory change from a vendor, a competitor, or a patient. All three are lagging indicators, and two of them have an incentive to distort.
The fix is thirty minutes a week, owned by one named person. Not a committee. A name.
Build the grid. Four columns: the substances you dispense, the states you’re licensed in, your certifier (LegitScript or equivalent), and the platforms you depend on to get paid — processor, pharmacy, EMR, ad networks. Every row is a thing that can change under you without notice.
Primary sources only. Federal Register, FDA warning-letter and advisory-committee pages, your state board’s meeting minutes, your certifier’s policy page. Vendor newsletters and LinkedIn posts are for finding items, never for confirming them. The confirmation is always the citation.
Log the nothing-weeks. This is the part everyone skips and it’s the part that makes the habit real. A dated line that reads “checked, nothing changed” is evidence of a monitoring program. Four months of blank calendar is evidence of nothing, and it’s the first thing anyone asks for when something goes wrong.
Have three responses ready, not one.
Green — note it, carry on.
Yellow — a change that affects a row in your grid. Someone owns a decision with a date on it.
Red — stop dispensing, call counsel, notify affected patients.
Decide what triggers this before you’re in it, because you will not think clearly the morning it lands.
The clinics that expanded their peptide catalog in August on the strength of a headline are the ones now asking their attorney what an advisory vote actually does. The clinics that spent thirty minutes reading the source document already knew, and spent August doing something else.
Thirty minutes. One name. Primary sources. That’s the whole program.
Before you go
New here? Most of you are — welcome. The Clinic Brief is a weekly read on what changed in the regulatory and business environment for cash-pay clinics, with the primary source attached every time.
Start with the free Processor-vs-EMR Reconciliation Worksheet. It’s the monthly pass that surfaced $58,000 in silently declined charges at one practice. Download it →
We’re also finishing the Clinic Operator’s Toolkit — the price-and-margin review, payment-rail map, weekly owner brief, and bleed diagnostic we use internally. Reply with “toolkit” and we’ll put you on the founding-price list before it goes public.
And tell us: who owns the regulatory half-hour at your clinic? Hit reply. We read everything.
— Devin & Ryan
The Clinic Brief is business and regulatory information, not legal or medical advice. Talk to qualified healthcare counsel about your specific situation.